[et_pb_section fb_built=”1″ _builder_version=”3.19.4″ use_background_color_gradient=”on” background_color_gradient_start=”rgba(0,151,202,0.69)” background_color_gradient_end=”rgba(0,85,147,0.8)” background_color_gradient_overlays_image=”on” background_image=”https://secureservercdn.net/198.71.233.106/d43.23a.myftpupload.com/wp-content/uploads/2017/10/bg.jpg” background_position=”top_center” custom_padding=”5%||5%” bottom_divider_style=”curve” bottom_divider_color=”#ffffff” bottom_divider_arrangement=”above_content” global_module=”6694″ saved_tabs=”all”][et_pb_row _builder_version=”3.19.4″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.4″ _dynamic_attributes=”content” text_font=”||||||||” header_font=”|700|||||||” header_text_color=”#ffffff” header_font_size=”60px” text_orientation=”center”]{“dynamic”:true,”content”:”post_title”,”settings”:{“before”:”

“,”after”:”

“}}[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.0.47″][et_pb_row use_custom_width=”on” custom_width_px=”960px” custom_padding=”33px|0px|0|0px|false|false” _builder_version=”3.19.4″ global_module=”6762″ saved_tabs=”all”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.4″ header_font=”||||||||” header_5_font=”|700||on|||||” header_5_font_size=”20px”]

COMPANY

At Arch Oncology, we are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. We are committed to advancing antibodies with best-in-class potential.

Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.  Our antibodies work by blocking the “don’t eat me” signal, the standard mechanism of anti-CD47 antibodies. Beyond blocking this signal, our antibodies also directly kill tumor cells. Importantly, our antibodies bind preferentially to tumor cells, instead of to normal cells, and bind even more potently to tumors in their acidic microenvironment (low pH).

Expanding our fight against cancer, we are advancing our lead anti-CD47 antibody AO-176 into clinical development for the treatment of patients with solid tumors.

We are aiming high in our fight against cancer. We are a team of highly experienced and driven professionals who are committed to excellence in all that we do. Our leadership team has successfully developed new drugs before. We know what we need to do to collaborate and execute to get the job done.

If you share this commitment and want to work with a team that is focused on helping patients, come aim high with us and apply.

[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row use_custom_width=”on” custom_width_px=”960px” _builder_version=”3.19.4″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.4″ header_font=”||||||||” header_5_font=”||||||||” header_5_font_size=”20px”]

POSITION LOCATION:

The Arch Oncology research labs are located in the Cortex Innovation Community in St. Louis, MO, near the Washington University School of Medicine and St. Louis University. Arch Oncology also has offices in the San Francisco Bay Area, CA. This position will be located in St. Louis.

REPORTS TO:

Director, Research

JOB DESCRIPTION AND RESPONSIBILITIES:
POSITION REQUIREMENTS AND EXPERIENCE:

Arch Oncology is an Equal Opportunity Employer and does not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class. Please send your CV and cover letter to info@archoncology.com.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”#0097ca” custom_margin=”0px||0px|” custom_padding=”0||0||true|false” top_divider_style=”curve2″ top_divider_color=”#ffffff” top_divider_flip=”vertical” global_module=”6648″ saved_tabs=”all”][et_pb_row custom_padding=”0|0px|0|0px|false|false” _builder_version=”3.19.4″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][/et_pb_column][/et_pb_row][/et_pb_section]

[et_pb_section fb_built=”1″ _builder_version=”3.19.4″ use_background_color_gradient=”on” background_color_gradient_start=”rgba(0,151,202,0.69)” background_color_gradient_end=”rgba(0,85,147,0.8)” background_color_gradient_overlays_image=”on” background_image=”https://secureservercdn.net/198.71.233.106/d43.23a.myftpupload.com/wp-content/uploads/2017/10/bg.jpg” background_position=”top_center” custom_padding=”5%||5%” bottom_divider_style=”curve” bottom_divider_color=”#ffffff” bottom_divider_arrangement=”above_content” global_module=”6694″ saved_tabs=”all”][et_pb_row _builder_version=”3.19.4″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.4″ _dynamic_attributes=”content” text_font=”||||||||” header_font=”|700|||||||” header_text_color=”#ffffff” header_font_size=”60px” text_orientation=”center”]{“dynamic”:true,”content”:”post_title”,”settings”:{“before”:”

“,”after”:”

“}}[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.0.47″][et_pb_row use_custom_width=”on” custom_width_px=”960px” custom_padding=”33px|0px|0|0px|false|false” _builder_version=”3.19.4″ global_module=”6762″ saved_tabs=”all”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.4″ header_font=”||||||||” header_5_font=”|700||on|||||” header_5_font_size=”20px”]

COMPANY

At Arch Oncology, we are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. We are committed to advancing antibodies with best-in-class potential.

Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.  Our antibodies work by blocking the “don’t eat me” signal, the standard mechanism of anti-CD47 antibodies. Beyond blocking this signal, our antibodies also directly kill tumor cells. Importantly, our antibodies bind preferentially to tumor cells, instead of to normal cells, and bind even more potently to tumors in their acidic microenvironment (low pH).

Expanding our fight against cancer, we are advancing our lead anti-CD47 antibody AO-176 into clinical development for the treatment of patients with solid tumors.

We are aiming high in our fight against cancer. We are a team of highly experienced and driven professionals who are committed to excellence in all that we do. Our leadership team has successfully developed new drugs before. We know what we need to do to collaborate and execute to get the job done.

If you share this commitment and want to work with a team that is focused on helping patients, come aim high with us and apply.

[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row use_custom_width=”on” custom_width_px=”960px” _builder_version=”3.19.4″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.4″ header_font=”||||||||” header_5_font=”||||||||” header_5_font_size=”20px”]

POSITION LOCATION

The Arch Oncology research labs are located in the Cortex Innovation Community in St. Louis, MO, near the Washington University School of Medicine and St. Louis University. Arch Oncology also has offices in the San Francisco Bay Area, CA. This  position will be located in St. Louis.

REPORTS TO

Senior Scientist, Research

JOB DESCRIPTION AND RESPONSIBILITIES
POSITION REQUIREMENTS AND EXPERIENCE

Arch Oncology is an Equal Opportunity Employer and does not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class. Please send your CV and cover letter to info@archoncology.com.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”#0097ca” custom_margin=”0px||0px|” custom_padding=”0||0||true|false” top_divider_style=”curve2″ top_divider_color=”#ffffff” top_divider_flip=”vertical” global_module=”6648″ saved_tabs=”all”][et_pb_row custom_padding=”0|0px|0|0px|false|false” _builder_version=”3.19.4″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][/et_pb_column][/et_pb_row][/et_pb_section]

[et_pb_section fb_built=”1″ _builder_version=”3.19.4″ use_background_color_gradient=”on” background_color_gradient_start=”rgba(0,151,202,0.69)” background_color_gradient_end=”rgba(0,85,147,0.8)” background_color_gradient_overlays_image=”on” background_image=”https://secureservercdn.net/198.71.233.106/d43.23a.myftpupload.com/wp-content/uploads/2017/10/bg.jpg” background_position=”top_center” custom_padding=”5%||5%” bottom_divider_style=”curve” bottom_divider_color=”#ffffff” bottom_divider_arrangement=”above_content” global_module=”6694″ saved_tabs=”all”][et_pb_row _builder_version=”3.19.4″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.4″ _dynamic_attributes=”content” text_font=”||||||||” header_font=”|700|||||||” header_text_color=”#ffffff” header_font_size=”60px” text_orientation=”center”]{“dynamic”:true,”content”:”post_title”,”settings”:{“before”:”

“,”after”:”

“}}[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.0.47″][et_pb_row use_custom_width=”on” custom_width_px=”960px” custom_padding=”33px|0px|0|0px|false|false” _builder_version=”3.19.4″ global_module=”6762″ saved_tabs=”all”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.4″ header_font=”||||||||” header_5_font=”|700||on|||||” header_5_font_size=”20px”]

COMPANY

At Arch Oncology, we are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. We are committed to advancing antibodies with best-in-class potential.

Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.  Our antibodies work by blocking the “don’t eat me” signal, the standard mechanism of anti-CD47 antibodies. Beyond blocking this signal, our antibodies also directly kill tumor cells. Importantly, our antibodies bind preferentially to tumor cells, instead of to normal cells, and bind even more potently to tumors in their acidic microenvironment (low pH).

Expanding our fight against cancer, we are advancing our lead anti-CD47 antibody AO-176 into clinical development for the treatment of patients with solid tumors.

We are aiming high in our fight against cancer. We are a team of highly experienced and driven professionals who are committed to excellence in all that we do. Our leadership team has successfully developed new drugs before. We know what we need to do to collaborate and execute to get the job done.

If you share this commitment and want to work with a team that is focused on helping patients, come aim high with us and apply.

[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row use_custom_width=”on” custom_width_px=”960px” _builder_version=”3.19.4″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.4″ header_font=”||||||||” header_5_font=”||||||||” header_5_font_size=”20px”]

POSITION LOCATION

At Arch Oncology, we have two bases. Our headquarters is in Brisbane, CA, a gateway of biotechnology innovation, and our scientific research laboratory is in St. Louis, MO, home of the Gateway Arch. This position is in Brisbane, CA.

REPORTS TO

Senior Director, Translational Medicine/Project Team Leadership (PTL)

JOB SUMMARY

We are seeking an experienced and dedicated Associate Director/Director, Project Management to play a key role in operational management to support the company programs. He/She will work closely with the Project Team Leader and Project Team (Clinical Development, Clinical Operations, Business Development, Translational Medicine, CMC, Regulatory and Research) to ensure cross functional alignment and deliverables. The successful candidate will work closely with team members to facilitate project progress, planning and execution, and to bridge internal activities with external expertise where appropriate. The ideal candidate is a team-player who is highly motivated, detail-oriented, can successfully multi-task, understands the broader context and impact of the support that he/she provides and knows how to identify or recognize issues and proactively propose solutions.

RESPONSIBILITIES WILL INCLUDE, BUT ARE NOT LIMITED TO, THE FOLLOWING
POSITION REQUIREMENTS AND EXPERIENCE
EDUCATION

Arch Oncology is an Equal Opportunity Employer and does not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class. Please send your CV and cover letter to info@archoncology.com.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”#0097ca” custom_margin=”0px||0px|” custom_padding=”0||0||true|false” top_divider_style=”curve2″ top_divider_color=”#ffffff” top_divider_flip=”vertical” global_module=”6648″ saved_tabs=”all”][et_pb_row custom_padding=”0|0px|0|0px|false|false” _builder_version=”3.19.4″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][/et_pb_column][/et_pb_row][/et_pb_section]